Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Toronova Suik
Generic Name
Ketorolac Tromethamine
Active Ingredient
KetorolacCategory
Nonsteroidal Anti-inflammatory Drug [EPC]
Salt Form
Tromethamine
Variants
2
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 30 mg/mL | INJECTION, SOLUTION | INTRAMUSCULAR, INTRAVENOUS | 80425-0455 |
| 30 mg/mL | INJECTION, SOLUTION | INTRAMUSCULAR, INTRAVENOUS | 76420-250 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Toronova Suik, you must consult a qualified healthcare professional.
Detailed information about Toronova Suik
Ketorolac tromethamine is a high-potency nonsteroidal anti-inflammatory drug (NSAID) used for the short-term management of moderately severe acute pain. It belongs to the pyrrolo-pyrrole group of non-narcotic analgesics.
Ketorolac dosing must be carefully managed to minimize the risk of severe side effects. The standard approach involves starting with a parenteral (IV or IM) dose and then transitioning to oral therapy if necessary. The total duration of treatment across all routes must not exceed five days.
Oral ketorolac is only indicated as a follow-up to IV or IM ketorolac. It should never be used as the initial therapy.
Ketorolac is not FDA-approved for use in pediatric patients under the age of 17 for oral or parenteral administration. However, it is occasionally used off-label in pediatric hospitals for short-term post-operative pain management under strict protocols. The ophthalmic solution is approved for children 2 years of age and older for allergic conjunctivitis and 3 years and older for post-cataract inflammation. Because of the high risk of renal toxicity and GI bleeding, pediatric use must be strictly supervised by a specialist.
Ketorolac is contraindicated in patients with advanced renal impairment and in patients at risk for renal failure due to volume depletion. For patients with moderately elevated serum creatinine, the dose should be reduced by half, and the total daily dose should not exceed 60 mg. Close monitoring of urine output and renal function tests is mandatory.
While ketorolac is primarily cleared renally, it is metabolized in the liver. Patients with impaired hepatic function should be monitored closely for signs of worsening liver enzymes. No specific dosage reduction is standardized for mild hepatic impairment, but the lowest effective dose should be used for the shortest possible time.
Patients over the age of 65 are at a significantly increased risk of gastrointestinal bleeding and acute kidney injury. Healthcare providers typically use the lower end of the dosing spectrum (15 mg IV/IM or 10 mg oral) and maintain strict adherence to the 5-day maximum duration.
Since ketorolac is usually given on a strict schedule in a hospital or for a very short duration at home, missing a dose should be addressed immediately. If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Never double the dose to catch up, as this significantly increases the risk of GI bleeding and kidney damage.
Signs of a ketorolac overdose may include severe abdominal pain, nausea, vomiting, gastrointestinal bleeding (manifesting as black/tarry stools or vomiting blood), lethargy, drowsiness, and rapid breathing. In severe cases, acute renal failure, hypertension, and coma can occur. If an overdose is suspected, contact a poison control center (1-800-222-1222) or seek emergency medical attention immediately. Treatment is primarily symptomatic and supportive; there is no specific antidote for ketorolac. Gastric lavage or activated charcoal may be used if the overdose is recent.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or extend the duration of treatment without medical guidance.
Ketorolac is a potent medication, and side effects are relatively common, particularly affecting the digestive system. Common side effects include:
Ketorolac is a high-alert medication due to its potency and narrow therapeutic window. It must never be used for more than five days. Patients must be screened for history of ulcers, kidney disease, and bleeding disorders before the first dose is administered. It is essential to stay well-hydrated while taking ketorolac to protect the kidneys. If you are scheduled for surgery, inform your surgeon that you are taking or have recently taken ketorolac, as it can increase the risk of bleeding during and after the procedure.
The FDA-mandated Black Box Warning for Ketorolac Tromethamine is among the most extensive for any non-opioid medication. It emphasizes that ketorolac is for short-term use only (maximum 5 days) and carries severe risks of gastrointestinal bleeding, ulceration, and perforation. It also highlights the risk of cardiovascular thrombotic events, including fatal heart attack and stroke. Furthermore, it is contraindicated in patients with advanced renal impairment, those at risk of volume depletion, and those with a history of hypersensitivity to aspirin or other NSAIDs. The warning also explicitly forbids use as a prophylactic analgesic before major surgery or during labor and delivery.
Certain medications must NEVER be used in combination with ketorolac due to the risk of life-threatening complications:
Ketorolac must NEVER be used in patients with the following conditions:
Ketorolac is generally avoided during pregnancy. According to FDA guidelines, use of NSAIDs like ketorolac at about 20 weeks gestation or later may cause fetal renal dysfunction leading to oligohydramnios (low amniotic fluid) and, in some cases, neonatal renal impairment. In the third trimester (starting at 30 weeks), ketorolac is strictly contraindicated because it may cause premature closure of the fetal ductus arteriosus (a vital heart vessel in the fetus) and lead to pulmonary hypertension in the newborn. It may also delay labor by inhibiting uterine contractions.
Ketorolac is excreted in human milk in small concentrations. While the amount transferred to the infant is generally considered low, the potential for serious adverse effects (such as GI bleeding or renal issues) in the nursing infant must be considered. Most clinicians advise caution, and some recommend avoiding breastfeeding during the 5-day course of treatment or using an alternative analgesic like acetaminophen.
Safety and effectiveness in pediatric patients under 17 years of age have not been established for systemic ketorolac. While it is used off-label in pediatric surgical centers, the risk of acute kidney injury is higher in children, especially those who are not well-hydrated. The ophthalmic form is approved for children 2 years and older.
Ketorolac is a potent inhibitor of the cyclooxygenase (COX) enzyme system. Specifically, it acts as a competitive antagonist for the active site of both COX-1 and COX-2 enzymes. By binding to these enzymes, it prevents the oxygenation of arachidonic acid into cyclic endoperoxides, which are the precursors to prostaglandins, thromboxanes, and prostacyclin. Ketorolac is considered one of the most potent COX-1 inhibitors available, which contributes to its high analgesic efficacy but also its significant gastrointestinal toxicity. The S-enantiomer is responsible for almost all the COX-inhibitory activity. Its EPC classification as an alpha-1 adrenergic agonist suggests potential minor interactions with vascular receptors, though this is not its primary clinical mechanism.
The primary pharmacodynamic effect of ketorolac is analgesia. It does not have significant sedative or anxiolytic properties. The onset of analgesic action following IM administration is approximately 30 minutes, with a peak effect occurring at 1 to 2 hours. The duration of analgesia is typically 4 to 6 hours. Unlike opioids, ketorolac does not cause miosis (pupil constriction) or significant respiratory depression. It does, however, cause a dose-related inhibition of platelet aggregation that lasts for 24 to 48 hours after discontinuation.
Common questions about Toronova Suik
Ketorolac is a potent nonsteroidal anti-inflammatory drug (NSAID) used specifically for the short-term management of moderately severe acute pain. It is most commonly used in hospital settings following major surgery to provide pain relief comparable to opioids without the risk of addiction. Because of its high potency and risk for side effects, it is only intended for use for five days or less. It is not suitable for minor aches, pains, or long-term chronic conditions like arthritis. Your doctor will typically start the medication through an injection (IV or IM) before switching you to oral tablets if needed.
The most common side effects of ketorolac involve the digestive system and the central nervous system. Many patients experience nausea, stomach pain, indigestion, or a burning sensation in the upper abdomen shortly after taking the medication. Other frequent side effects include headaches, dizziness, and a feeling of drowsiness or lethargy. Some patients may also notice swelling in their ankles or feet due to fluid retention. Because ketorolac is very strong, these side effects can occur even with short-term use. If you notice any signs of severe stomach pain or black stools, you should contact your healthcare provider immediately.
No, you should not drink alcohol while taking ketorolac. Alcohol is a known irritant to the stomach lining and can significantly increase the risk of developing stomach ulcers or gastrointestinal bleeding when combined with NSAIDs. Since ketorolac is one of the most potent NSAIDs available, the risk of a serious bleed is much higher than with over-the-counter medications like ibuprofen. Even a small amount of alcohol can trigger severe gastric distress or worsen the kidney-straining effects of the drug. Always wait until you have finished your full course of ketorolac and the drug has cleared your system before consuming alcohol.
Ketorolac is generally not recommended during pregnancy and is strictly contraindicated in the third trimester. Taking ketorolac after 20 weeks of pregnancy can lead to low levels of amniotic fluid and potential kidney problems for the developing fetus. In the third trimester (after 30 weeks), it can cause the premature closure of a vital heart vessel in the baby called the ductus arteriosus, which can lead to life-threatening lung issues after birth. It may also interfere with the start of labor or cause excessive bleeding during delivery. If you are pregnant or planning to become pregnant, you must discuss safer pain management alternatives with your obstetrician.
The onset of action for ketorolac depends on how it is administered. When given by intravenous (IV) injection, pain relief can begin within minutes, while intramuscular (IM) injections typically take about 30 minutes to start working. For the oral tablet form, it usually takes 30 to 60 minutes to reach peak levels in the bloodstream and begin providing significant relief. The maximum pain-relieving effect is generally felt about 1 to 2 hours after the dose is taken. The effects typically last for about 4 to 6 hours, which is why it is often dosed every 6 hours on a fixed schedule.
Yes, you can stop taking ketorolac suddenly without experiencing withdrawal symptoms, as it is not an opioid and does not cause physical dependence. In fact, ketorolac is designed to be stopped as soon as your severe pain is manageable or once you reach the 5-day limit. There is no need to taper the dose or slowly reduce it. However, you should always follow the specific duration prescribed by your doctor. If you stop the medication because of a side effect, such as stomach pain or a rash, be sure to inform your healthcare provider so they can update your medical records regarding NSAID sensitivities.
If you miss a dose of ketorolac, you should take it as soon as you remember. However, if it is nearly time for your next scheduled dose, it is safer to skip the missed dose and simply take the next one at the regular time. You should never take two doses at once or 'double up' to make up for a missed one, as this greatly increases the risk of damaging your stomach lining or your kidneys. Because ketorolac is often used for very intense pain, keeping a consistent schedule is important for effective pain control. If you are unsure what to do, call your pharmacist or doctor for guidance.
Ketorolac does not cause traditional weight gain in the form of increased body fat, but it can cause rapid weight gain due to fluid retention. Like many NSAIDs, ketorolac can cause the body to hold onto sodium and water, leading to edema (swelling) in the legs, ankles, and hands. This fluid-related weight gain can occur quite quickly, sometimes within just a few days of starting the medication. If you notice a sudden increase in weight or significant swelling, you should notify your doctor, as this can be a sign of strain on your kidneys or heart. This effect usually resolves once the medication is discontinued.
Ketorolac has many significant drug interactions and should be used with extreme caution alongside other medications. It should never be taken with other NSAIDs (like aspirin, ibuprofen, or naproxen) or with blood thinners like warfarin, as this creates a very high risk of life-threatening bleeding. It can also interfere with blood pressure medications, diuretics, and certain psychiatric drugs like lithium. Because it is highly protein-bound, it can 'bump' other drugs off their transport proteins in the blood, potentially making them more toxic. Always provide your healthcare provider with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you are currently taking.
Yes, ketorolac tromethamine is widely available as a generic medication in several forms, including oral tablets and injectable solutions. The generic versions are bioequivalent to the original brand-name versions, such as Toradol, which has been discontinued in the United States but remains a well-known name for the drug. Generic ketorolac is typically much more affordable than brand-name alternatives and is covered by most insurance plans. Despite being generic, it remains a high-potency medication that requires a prescription and strict medical supervision. Always ensure you are receiving the correct strength and following the 5-day usage limit regardless of whether you use the brand or generic.
Other drugs with the same active ingredient (Ketorolac)
> Warning: Stop taking Ketorolac and call your doctor immediately if you experience any of these.
Ketorolac is strictly contraindicated for long-term use. If used beyond 5 days, the risk of the following increases exponentially:
The FDA has issued a comprehensive Black Box Warning for ketorolac, which is one of the most stringent in the NSAID class. The warning covers several critical areas:
Report any unusual symptoms to your healthcare provider immediately.
For patients receiving ketorolac in a hospital setting, healthcare providers will typically monitor:
Ketorolac may cause dizziness, drowsiness, or visual disturbances in some patients. You should not drive, operate heavy machinery, or engage in hazardous activities until you know how the medication affects you. If you feel lightheaded or sleepy, avoid these tasks and consult your doctor.
Alcohol consumption should be strictly avoided while taking ketorolac. Alcohol significantly increases the risk of gastrointestinal irritation and bleeding. Combining the two can lead to rapid development of stomach ulcers or severe gastritis.
Because ketorolac is only used for 5 days or less, there is no risk of a 'withdrawal syndrome' like that seen with opioids. However, the drug should be stopped immediately if any signs of an allergic reaction, GI bleed, or kidney dysfunction occur. There is no need for tapering when used for the indicated short duration.
> Important: Discuss all your medical conditions with your healthcare provider before starting Ketorolac.
For each major interaction, the mechanism typically involves either the competitive inhibition of renal transporters (like with Lithium or Methotrexate) or the synergistic inhibition of physiological pathways (like the dual inhibition of platelets with anticoagulants). The management strategy usually involves avoiding the combination or performing frequent laboratory monitoring of renal function and drug levels.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
These conditions require a careful risk-benefit analysis by a physician:
There is a high rate of cross-sensitivity between ketorolac and other NSAIDs. If a patient has experienced hives, swelling, or bronchospasm after taking aspirin, naproxen, or ibuprofen, they are highly likely to have a similar or more severe reaction to ketorolac. This is known as 'NSAID-exacerbated respiratory disease' (NERD).
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Ketorolac.
Patients over age 65 are at the highest risk for severe complications from ketorolac. Age-related declines in renal function mean that the drug stays in the body longer, increasing the risk of toxicity. The FDA recommends using the lowest possible dose (15 mg IV/IM or 10 mg oral) and monitoring these patients very closely for signs of GI bleeding or kidney failure. Geriatric patients are also more susceptible to the cardiovascular risks of NSAIDs.
Ketorolac is cleared almost entirely by the kidneys. In patients with serum creatinine levels indicating mild to moderate impairment, the dose must be reduced by 50%, and the daily maximum should not exceed 60 mg. In patients with advanced renal disease (Scr > 3.0 mg/dL), the drug is absolutely contraindicated. It is not significantly removed by hemodialysis.
Patients with impaired hepatic function (e.g., Child-Pugh Class A or B) do not typically require a dose adjustment, but they should be monitored for signs of worsening liver function. In patients with severe cirrhosis, the risk of developing 'hepatorenal syndrome' is increased when using potent NSAIDs like ketorolac.
> Important: Special populations require individualized medical assessment.
| Parameter | Value |
|---|---|
| Bioavailability | 80% - 100% |
| Protein Binding | >99% |
| Half-life | 5 - 6 hours (up to 12h in elderly) |
| Tmax | 0.5 - 1.0 hours (oral) |
| Metabolism | Hepatic (Glucuronidation/Hydroxylation) |
| Excretion | Renal 91%, Fecal 6% |
Ketorolac tromethamine is a member of the pyrrolo-pyrrole group of nonsteroidal anti-inflammatory drugs. Its chemical name is (±)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, compounded with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1). The molecular formula is C15H13NO3 · C4H11NO3, and its molecular weight is 376.41 g/mol. It is a white to off-white crystalline powder that is highly soluble in water and methanol.
Ketorolac is classified as a non-selective NSAID. Within the NSAID category, it is further grouped into the heteroaryl acetic acid derivatives, alongside drugs like indomethacin and diclofenac. It is distinct from the propionic acid derivatives (like ibuprofen) and the oxicams (like piroxicam) due to its unique pyrrolo-pyrrole structure and its exceptional potency as an analgesic.